In vivo supplementation studies of the antioxidant α-tocopherol in human Type II diabetes have used surrogate, rather than direct, markers of oxidative damage/antioxidant protection and have used higher doses of α-tocopherol than used in coronary secondary prevention trials. We tested the hypothesis that oral α-tocopherol in a dosage regimen used in secondary prevention trials would reduce directly observed oxidatively induced single-strand breaks in lymphocyte DNA in Type II diabetes. We studied 40 people with Type II diabetes and 30 controls in a randomized, double-blind, placebo-controlled trial of 400 i.u. of oral α-tocopherol daily for 8 weeks. Lymphocyte DNA single-strand breaks and low-density lipoprotein (LDL) particle size and oxidizability were measured at baseline, after 8 weeks, and after 4 weeks washout. Polymorphisms in the gene for the antioxidant enzyme paraoxonase-1 gene (position 192) were measured. The diabetics had increased DNA oxidative susceptibility (P l 0.008), without increased LDL oxidative susceptibility. There was a direct relationship between DNA oxidative susceptibility and baseline plasma α-tocopherol in the diabetes group alone (r l 0.421, r 2 l 0.177 and P l 0.023), but DNA and LDL oxidative susceptibility were not influenced by α-tocopherol supplementation in either group in this regimen. Paraoxonase-1 gene polymorphisms did not contribute to LDL or DNA oxidative susceptibility or response to α-tocopherol. Increased DNA oxidative susceptibility, therefore, can occur in Type II diabetes without increased LDL oxidative susceptibility, but α-tocopherol supplementation in this regimen has no influence on DNA or LDL oxidative susceptibility in Type II diabetes or controls. Polymorphisms in the paraoxonase gene (position 192) are not associated with differences in oxidative susceptibility or responses to α-tocopherol.
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hyperglycaemia promotes atherogenic oxidative damage to lipoproteins, proteins and DNA [1] . Epidemiological studies and one secondary prevention trial have suggested that α-tocopherol supplementation can reduce vascular event rates in people without diabetes [2] , but this finding has not been reproduced in more recent large, powerful prospective clinical trials in non-diabetic populations at high coronary risk [3, 4] , and the full results of the Heart Protection Study (which has a large antioxidant-treated diabetic subgroup) are awaited [5] .
Antioxidant studies in vitro have shown that many pro-atherogenic processes are sensitive to oxidative balance, such as vascular cell adhesion molecule expression and the expression of matrix metalloproteinases in vascular plaque [6, 7] . However, the available in vivo clinical studies of α-tocopherol supplementation in human Type II diabetes have all used surrogates for oxidative damage\antioxidant protection, rather than available methods for direct observation of oxidatively induced damage, such as the detection of single-strand breaks in lymphocyte DNA [8] [9] [10] [11] , have used α-tocopherol dosages higher than those used in secondary prevention trials [3, 4, [12] [13] [14] , and have not examined potential mediators of antioxidant sensitivity, such as polymorphisms in the paraoxonase-1 (PON-1) gene which encodes a high-density lipoprotein (HDL)-associated antioxidant enzyme that influences lowdensity lipoprotein (LDL) oxidizability [15] .
We hypothesised that α-tocopherol supplementation would lessen DNA oxidative susceptibility and carried out a randomized, prospective, double-blind, placebocontrolled trial of α-tocopherol supplementation for 8 weeks in subjects with and without Type II diabetes.
METHODS Subjects
After local ethical committee approval and written informed consent, we studied 40 people with Type II diabetes and 30 gender-matched controls. Patients with Type II diabetes were recruited if they were Caucasian, non-vegetarian, non-smokers, who were taking no dietary supplements or any medication other than oral hypoglycaemics. A total of 21 patients took sulphonylurea drugs (either alone or in combination with metformin), nine took metformin alone and 10 were managed with diet alone. Patients with diabetic nephropathy (defined as albustix positive proteinuria or an elevated urinary albumin to creatinine ratio on an early morning urine sample) were excluded. No patient had a clinically expressed history of coronary artery disease, 10 had background retinopathy and 10 had evidence of a peripheral sensorimotor neuropathy. Non-diabetic controls fulfilled the same criteria, and were recruited from medical and nursing staff or the general population, and all had a fasting plasma glucose below 6.1 mM. Two diabetic patients were withdrawn from the study during follow-up because of stated poor compliance with the study protocol. These patients were excluded from the analysis of the study, but did not differ from those remaining in any variable displayed in Table 1 , which includes baseline data on all patients.
Experimental design
Subjects were recruited into a double-blind prospective trial for 8 weeks, and randomized to take either 400 i.u. D-α-tocopherol (Henkel Corporation, La Grange, IL, U.S.A.) or a gelatine placebo. Two baseline fasting venous blood samples (25 ml) were taken from each volunteer, with a 2-week interval between samples, for measurement of single-strand breaks in lymphocyte DNA, plasma antioxidant concentrations, lipoprotein oxidizability and particle size, and measures of glycaemic control. Samples were then also taken after 8 weeks supplementation, and 4 weeks after supplementation had ceased. Measurements of DNA single-strand breaks were made in a smaller sample of these subjects (31 with Type II diabetes and 16 controls). Single-cell gel electrophoresis (comet assay) was performed using the method described by Singh et al [8] . This well-validated method uses direct fluorescent microscopy of ethidium bromide-stained lymphocyte DNA on an agarose gel. DNA single-strand breaks led to relaxation of DNA supercoiling and a ' comet ' appearance on electrophoresis. The size of the tail on the comet and the distribution of the fluorescence are in direct proportion to the number of single-strand breaks, and even low levels of endogenous or oxidatively induced DNA damage are detectable with this system [8] [9] [10] [11] . DNA single-strand breaks were calculated for basal control samples [control tail moment (CTM) reflecting basal levels of single-strand breaks], for hydrogen peroxide (100 µM)-treated samples [treated tail moment (TTM) as a measure of DNA oxidative susceptibility], and DTM, the difference in tail moment between TTM and CTM]. We have described this methodology previously in more detail [11] , and DNA damage, characteristic of oxidative, toxic or mutagenic insult, is most frequently measured in lymphocytes [16] . In the absence of infection, lymphocytes are relatively metabolically inactive, exhibiting long-term environmental exposure to both diet and mutagenic insult. Lymphocytes can be stimulated under controlled conditions, and their growth involves reactions required by any other developing proliferating cell [17] . The coefficient of variation of comet measurements is less than 0.1 %.
Plasma α-tocopherol and carotenoid concentrations were measured using a modified HPLC method [18] , and ascorbic acid analysis was performed using the method of Finglas et al. [19] . Plasma α-tocopherol and carotenoid levels were corrected for plasma total cholesterol concentrations taken at the same time. Polymorphisms at position 192 in the PON-1 gene, which encodes the HDL-associated antioxidant enzyme paraoxonase, were analysed as described elsewhere [20] . Fasting lipid profiles were assessed using commercially available kits (Roche Diagnostics, Welwyn Garden City, Herts, U.K.) on an automated biochemistry analyser (COBAS MIRA ; Roche Diagnostics). The measurement of LDL oxidizability (i.e. determining the delay or lag in conjugated α-Tocopherol, DNA damage and Type II diabetes diene production at 234 nm by copper-stimulated oxidation) was based on the method described by Kleinveld et al. [21] , where LDL oxidation and electrophoresis are carried out on LDL isolated by ultracentrifugation, with a final copper concentration of 0.5 µM. Relative LDL particle size was assessed by agarose gel electrophoresis on a commercially available buffered agarose gel (Pragon Lipo ; Beckman Instruments, High Wycombe, Bucks., U.K.). Glycosylated haemoglobin (HbA1c) was assessed using a commercially available kit (Roche Diagnostics), with the normal range quoted as 4.5-5.7 %. The mean of paired baseline measurements (CTM, TTM, LDL lag phase and plasma antioxidant concentrations) were taken as the baseline value.
Statistical analysis
All variables were normally distributed and data are expressed as meanspS.D. Within-group differences during the prospective study were analysed by one-way ANOVA for repeated measures, followed by a paired t test when a significant (P 0.05) difference was found within a group. The impact of α-tocopherol supplementation on a variable was measured by two-way (α-tocopherol versus placebo) repeated measures ANOVA. 
RESULTS

Clinical features
Patients with Type II diabetes were older and more centrally obese than controls, and had inadequate glycaemic control (Table 1) .
Plasma antioxidant profiles
At baseline, the diabetes group had significantly higher plasma α-tocopherol concentrations than controls (P 0.0001). Other plasma antioxidant concentrations did not differ significantly between groups except for plasma β-carotene, which was lower in the diabetes group (P l 0.034). Plasma α-tocopherol increased 1.48-fold in the α-tocopherol-supplemented group with Type II diabetes, and was significantly higher than in the matched placebo group after 8 weeks (P l 0.0004). In the nondiabetic group, plasma α-tocopherol rose 1.54-fold in the α-tocopherol-supplemented group (P l 0.059 compared with the matched placebo group after 8 weeks) ( Table 2) .
DNA single-strand breaks and susceptibility to oxidative damage
At baseline, the diabetes group had a similar mean CTM compared with controls, but increased susceptibility to hydrogen peroxide-induced DNA damage ex vivo (TTM, P l 0.008 ; DTM ; P l 0.005). α-Tocopherol supplementation had no significant impact on these measurements in either the diabetes or control group (Table 3) .
Determinants of DNA single-strand breaks at baseline
CTM was unrelated to any measured variable in either group. In the diabetics, the only significant independent relationship on multiple regression, was a significant direct relationship between DTM and corrected plasma α-tocopherol at baseline (r l 0.421, r# l 0.177 and P l 0.023) and a weaker direct relationship for TTM and corrected plasma α-tocopherol (r l 0.35, r# l 0.177 and P l 0.06). In the control group, however, there was no Within each group, age was not significantly related to any comet assay measurement (P 0.1), and age was not a significant independent variable in the total sample (diabetic and control groups combined) when groups were included in multiple regression (P 0.4).
LDL oxidizability and particle size
At baseline, the diabetes and control groups did not differ in mean LDL lag times. α-Tocopherol supplementation had no significant impact on LDL lag times in the α-Tocopherol, DNA damage and Type II diabetes diabetes or control groups (Table 3) . Mean LDL particle size was lower in the Type II diabetes group (P l 0.007) and α-tocopherol supplementation had no significant impact on LDL particle size in either group (all P 0.2).
PON-1 192 polymorphisms
In the diabetes group, 35 patients were successfully genotyped, of whom 17 (48 %) were QQ 192 homozygotes, 16 (46 %) were QR 192 heterozygotes, and two (6 %) were RR 192 homozygotes. Comparison of those with an R allele and those without showed no significant difference at baseline in LDL lag times (P l 0.12), in DNA oxidative damage (CTM, TTM and DTM, all P 0.5) or in the lack of response in these variables to α-tocopherol (all P 0.4). In the controls, 26 patients were successfully genotyped : 12 (46 %) were QQ 192 homozygotes, 11 (42 %) were QR 192 heterozygotes, and three (12 %) were RR 192 homozygotes. Comparison of those with an R allele and those without showed no significant difference at baseline in LDL lag times (P l 0.61), in DNA oxidative damage (CTM, TTM and DTM, all P 0.5) or in the lack of response in these variables to α-tocopherol (all P 0.2).
DISCUSSION
We have shown greatly increased susceptibility of lymphocyte DNA to oxidative damage in Type II diabetes using alkaline single-cell gel electrophoresis (comet assay), which gives a direct and quantifiable, rather than a surrogate, measure of the balance between DNA damage and repair, and of DNA oxidative susceptibility [8] [9] [10] [11] . This abnormality was present without changes in LDL oxidative susceptibility, and neither α-tocopherol supplementation nor PON-1 gene polymorphisms influenced DNA or LDL oxidizability in diabetics or controls. Several factors could be contributing to increase DNA oxidative susceptibility in the Type II diabetes group. Non-enzymic glycation of DNA bases [22] , generation of lipid peroxidation products [23] , differences in paraoxonase activity [24] , generation of reactive oxygen species [25] and elevated glucose concentrations [26] have all been associated with evidence of increased DNA damage, and these changes are likely to have been more prevalent in the Type II diabetes group. The lack of difference between the groups in basal DNA singlestrand break rates (CTM), but with an increased rate of single-strand breaks in the diabetes group on exposure to oxidative stress (TTM), may imply that the processes outlined above retard DNA repair, and that this existing unrepaired damage to DNA bases is only manifest when converted initially into abasic sites during oxidative attack and later to single-strand breaks on electrophoresis.
The present baseline data are supported by small studies describing increased DNA damage in Type II diabetes [27, 28] , and other groups have shown increased production of monocyte or urinary 8-hydroxydeoxyguanosine (a major oxidative base modification found in DNA) in some diabetes populations [29, 30] . Some caution is required, however, in interpreting 8-hydroxydeoxyguanosine data [11] . It is not known if the increased DNA oxidative susceptibility demonstrated in the present study could contribute to microvascular or macrovascular morbidity in Type II diabetes, although others [29] have made this speculation for microvascular disease. If increased oxidative DNA susceptibility in Type II diabetes led to increased rates of cell apoptosis in situations of high oxidative stress, such as vascular plaque, this could lead to increased plaque instability and vascular event rates [31] .
In our previous study of a population of Type I diabetics and controls [11] , we found that the Type I diabetes group had lower levels of oxidative DNA damage than controls, a finding also reported by Anderson et al. [32] . It has been suggested that this finding in Type I diabetes is due to increased efficiency of DNA repair in states of chronic low-level oxidant stress [32] , and this possibility is supported by in vitro studies of low-level radiation-induced damage [33] . The implication is that repair processes in Type II diabetes may be less efficient, perhaps as a result of increased levels of oxidant stress and damage to repair processes, or as a combination of hyperglycaemia and increased age [34] .
Short-term α-tocopherol supplementation in vivo reduces LDL oxidizability in Type II diabetes [12] [13] [14] , but these studies have used higher dosages of between 800 to 1600 i.u. of α-tocopherol daily. The lack of α-tocopherol effect on DNA and\or LDL oxidizability in the present study may be due to the 'low'-dosage regimen chosen, although 400 i.u. daily is the minimum dose needed to influence LDL oxidizability in titration studies [35] , or to the antioxidant itself. Dietary supplementation with antioxidant flavonoids lessens DNA single-strand breaks in elderly patients with Type II diabetes [36] , but α-tocopherol did not do so in the present study. The flavonoids are hydrophilic, and hydrophilic free radical scavengers may be, therefore, more active within nuclear and mitochondrial compartments than the hydrophobic antioxidants (such as α-tocopherol and the carotenoids) used in this study, which are more associated with cellular membranes [37] . There are no trials of flavonoid supplementation as a primary or secondary antioxidant vascular intervention, and no comparator trials of efficacy of α-tocopherol and flavonoids in LDL or DNA oxidizability. This may be important in view of the relative lack of efficacy of α-tocopherol as a secondary coronary prevention agent, although the results of the Heart Protection Study, which has an antioxidant wing and studies a variety of high vascular risk diabetic groups, are awaited [5] . In a previous study in Type I diabetes patients [11] we demonstrated that this dose of α-tocopherol did prolong LDL lag times in the control group, but this was not the case in the present control group. This may reflect differences due to agerelated changes in LDL composition and oxidizability, since the present control group were substantially older than in the previous study [11, 38] .
We found no difference in in vitro LDL lag times between non-smoking Type II diabetic patients with reasonable glycaemic control and without macrovascular complications and controls. Many publications in the last decade have examined LDL oxidizability, using broadly similar methodologies, in Type II diabetes, and studies comparable in size and patient definition to the present study [39] have also found no, or minimal, differences in LDL oxidizability in Type II diabetes patients with reasonable glycaemic control and no macrovascular complications, although this has not been an invariable finding, and in vitro glycation of LDL apolipoprotein B increases oxidative susceptibility [40] . The present study suggests that abnormalities in DNA oxidative susceptibility are present in Type II diabetes when surrogate methods for lipoprotein oxidizability are normal.
The complexity of the relationships between PON-1 gene polymorphisms, enzyme activities, LDL protection and coronary event rates or coronary disease has been well reviewed [15] . The endogenous substrate(s) for HDL-associated PON-1 enzyme in vivo are uncertain, but may be biologically active phospholipid arachidonic acid derivatives in LDL [41] or lipoprotein linoleic acid derivatives [42] . The copper oxidation of LDL used in the present study measures the lag time before the generation of these products is detectable at 234 nm, and it seems reasonable to assume that variations of in vivo PON enzyme activity associated with HDL might influence the in vivo LDL generation of these products and the ex vivo lag time before their appearance on LDL copper oxidation ; however, we found no relationship in the present study. Others [24] have demonstrated an association between PON-1 55 polymorphisms and some measures of oxidative DNA damage (urinary 8-hydroxydeoxyguanosine), although the use of this method is open to criticism [11] and the mechanism behind the association is unclear. The present study does not support such an association between 192-polymorphisms using a better marker of DNA damage\repair.
It is not possible to confirm that the increased plasma α-tocopherol concentrations in the diabetes group indicate increased bioavailability, and a weakness of the present study is that dietary histories and analyses were not undertaken. Recent data have shown that elevated plasma, LDL and very-low-density lipoprotein α-tocopherol concentrations can be a feature of Type II diabetes [43] , and this may be due to increased hepatic mRNA and expression of α-tocopherol transfer protein, leading to increased incorporation of α-tocopherol into lipoproteins and increased peripheral bioavailability [44] . α-Tocopherol can act as a pro-oxidant in some situations associated with pre-existing increased oxidative stress, since increased oxidative stress can free transition metal ions from cell metalloproteins which promote free radical damage particularly in the reduced state [45, 46] . Theoretically an antioxidant such as α-tocopherol could perpetuate this process by maintaining free transition metal ions in a reduced state and promoting lipoprotein and DNA oxidative damage [45, 46] . In this context, the baseline direct association between α-tocopherol and oxidative DNA susceptibility in the diabetics, but not the controls, is interesting, but the weakness of the relationship and the lack of a pro-oxidant effect of α-tocopherol supplementation precludes further speculation on any pro-oxidant actions of α-tocopherol in Type II diabetes.
In summary, we found that people with Type II diabetes in reasonable glycaemic control have increased DNA oxidative susceptibility without increased LDL oxidative susceptibility compared with controls, and α-tocopherol supplementation had no significant effect on these measurements. PON-1 polymorphisms at position 192 do not influence LDL or DNA oxidative susceptibility or responses to α-tocopherol in diabetics or controls.
